Litigation Details for Novartis Pharmaceuticals Corporation v. Mylan Inc. (N.D.W. Va. 2014)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Mylan Inc. (N.D.W. Va. 2014)
| Docket | ⤷ Try a Trial | Date Filed | 2014-06-26 |
| Court | District Court, N.D. West Virginia | Date Terminated | 2015-10-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Irene Patricia Murphy Keeley |
| Jury Demand | None | Referred To | |
| Patents | 6,465,504; 6,596,750 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Mylan Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Novartis Pharmaceuticals Corporation v. Mylan Inc. (N.D.W. Va. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | 36 | claims of U.S. Patent Nos. 6,465,504 (“the ’504 Patent”) and 6,596,750 (“the ’750 Patent”) are invalid…Declaratory Judgment of Non-Infringement of the ’504 Patent) -2-…that Mylan is liable for infringement of the ’504 Patent. Novartis denies any and all remaining allegations…Declaratory Judgment of Non-Infringement of the ’750 Patent) 28. Novartis hereby incorporates the…that Mylan is liable for infringement of the ’750 Patent. Novartis denies any and all remaining allegations | External link to document | |
| 0000-00-00 | 38 | 3 Patent No. 6,465,504 (“the ‘504 Patent”), issued on October 15, 2002, and Patent No. 6,596,…that the patent has expired; (3) the date on which the patent will expire; or, (4) that the patent is invalid…judgment that Mylan infringed its patents; 2) a judgment that the patents are valid and enforceable; 3) …four conditions regarding the patent status of the brand drug: (1) that patent information for the brand …any infringement of Novartis’ patents, and countering that the patents are invalid (Dkt. No. 31 at 17 | External link to document | |
| 0000-00-00 | 46 | claims of Novartis’s U.S. Patent No. 6,465,504 (the “’504 patent”) is invalid. Discovery will…and validity/invalidity of the patents-in-suit. The patents-in-suit have already been litigated… more claims of Novartis’s U.S. Patent No. 6,596,750 (the “’750 Patent”) is invalid. Discovery…infringes one or more claims of the ’504 patent or ’750 patent literally or under the doctrine… 2015, Novartis shall produce the patents-in-suit and associated prosecution | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
